These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 36788940)

  • 21. Favorable effects of inhaled treprostinil in severe pulmonary hypertension: results from randomized controlled pilot studies.
    Voswinckel R; Enke B; Reichenberger F; Kohstall M; Kreckel A; Krick S; Gall H; Gessler T; Schmehl T; Ghofrani HA; Schermuly RT; Grimminger F; Rubin LJ; Seeger W; Olschewski H
    J Am Coll Cardiol; 2006 Oct; 48(8):1672-81. PubMed ID: 17045906
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination therapy with riociquat and inhaled treprostinil in inoperable and progressive chronic thromboembolic pulmonary hypertension.
    Swisher JW; Elliott D
    Respir Med Case Rep; 2017; 20():45-47. PubMed ID: 27942445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and efficacy of transition from inhaled treprostinil to parenteral treprostinil in selected patients with pulmonary arterial hypertension.
    Preston IR; Feldman J; White J; Franco V; Ishizawar D; Burger C; Waxman AB; Hill NS
    Pulm Circ; 2014 Sep; 4(3):456-61. PubMed ID: 25621159
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease.
    Oudiz RJ; Schilz RJ; Barst RJ; Galié N; Rich S; Rubin LJ; Simonneau G;
    Chest; 2004 Aug; 126(2):420-7. PubMed ID: 15302727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence-based pharmacologic management of pulmonary arterial hypertension.
    Benedict N; Seybert A; Mathier MA
    Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Inhaled Treprostinil Palmitil, Inhaled and Intravenous Treprostinil, and Oral Selexipag in a Sugen/Hypoxia Rat Model of Pulmonary Arterial Hypertension.
    Corboz MR; Plaunt AJ; Malinin VS; Li Z; Gauani H; Chun D; Cipolla D; Perkins WR; Chapman RW
    J Pharmacol Exp Ther; 2022 Oct; 383(1):103-116. PubMed ID: 36507843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension.
    Gessler T; Seeger W; Schmehl T
    Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.
    Parikh KS; Rajagopal S; Fortin T; Tapson VF; Poms AD
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):322-5. PubMed ID: 26828324
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and Safety of Inhaled Iloprost in Japanese Patients With Pulmonary Arterial Hypertension　- Insights From the IBUKI and AIR Studies.
    Saji T; Myoishi M; Sugimura K; Tahara N; Takeda Y; Fukuda K; Olschewski H; Matsuda Y; Nikkho S; Satoh T
    Circ J; 2016; 80(4):835-42. PubMed ID: 27001191
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension.
    Lindegaard Pedersen M; Krüger M; Grimm D; Infanger M; Wehland M
    Basic Clin Pharmacol Toxicol; 2020 Jan; 126(1):32-42. PubMed ID: 31403254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and tolerability of LIQ861, a novel dry-powder formulation of treprostinil.
    Roscigno R; Vaughn T; Anderson S; Wargin W; Hunt T; Hill NS
    Pulm Circ; 2020; 10(4):2045894020971509. PubMed ID: 33282202
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostanoids for pulmonary arterial hypertension.
    Galiè N; Manes A; Branzi A
    Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treprostinil for the treatment of pulmonary arterial hypertension.
    Torres F; Rubin LJ
    Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
    White RJ; Jerjes-Sanchez C; Bohns Meyer GM; Pulido T; Sepulveda P; Wang KY; Grünig E; Hiremath S; Yu Z; Gangcheng Z; Yip WLJ; Zhang S; Khan A; Deng CQ; Grover R; Tapson VF;
    Am J Respir Crit Care Med; 2020 Mar; 201(6):707-717. PubMed ID: 31765604
    [No Abstract]   [Full Text] [Related]  

  • 36. Oral treprostinil in transition or as add-on therapy in pediatric pulmonary arterial hypertension.
    Ivy DD; Feinstein JA; Yung D; Mullen MP; Kirkpatrick EC; Hirsch R; Austin ED; Fineman J; Truong U; Solum D; Deng CQ; Hopper RK
    Pulm Circ; 2019; 9(3):2045894019856471. PubMed ID: 31215336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different efficacy of inhaled and oral medications in pulmonary hypertension.
    AbuHalimeh BJ; Parambil JG; Tonelli AR
    Heart Lung; 2017; 46(4):334-337. PubMed ID: 28527831
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
    Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
    J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects.
    Roscigno RF; Vaughn T; Parsley E; Hunt T; Eldon MA; Rubin LJ
    Vascul Pharmacol; 2021 Jun; 138():106840. PubMed ID: 33545364
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Survival and drug persistence in patients receiving inhaled treprostinil at doses greater than 54 µg (nine breaths) four times daily.
    Shapiro S; Mandras S; Restrepo-Jaramillo R; Shen E; Broderick M; Rao Y; Lee D; Nelsen AC
    Pulm Circ; 2021; 11(4):20458940211052228. PubMed ID: 34733493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.